Abstract Introduction South America is one of the regions most affected by the COVID‐19
pandemic. Specific and affordable treatments are needed to treat SARS‐CoV‐2 infection …

Objectives Being COVID-19 convalescent plasma (CCP) a therapeutic option that can have
a potential impact on the normalization of immunological parameters of COVID-19 affected …

Convalescent plasma (CP) therapy has been suggested as a treatment for emerging viral
diseases. Moreover, many studies have been conducted to evaluate the efficacy of COVID …

Background The utility of convalescent coronavirus disease 2019 (COVID-19) plasma (CCP)
in the current pandemic is not well defined. We sought to evaluate the safety and efficacy of …

Convalescent plasma (CP) transfusion has been utilized as a salvage therapy in
immunocompromised patients with severe COVID‐19 pneumonia. We describe the case of …

Convalescent plasma to treat coronavirus disease 2019 (COVID-19) is currently the focus of
numerous clinical trials worldwide, but the criteria of treatment efficacy remain largely …

Currently, there are no effective treatments for novel corona virus disease 2019 (COVID-19).
In this study, we report the preliminary results on the efficacy and safety of convalescent …

Background The convalescent plasma of patients who recover from coronavirus disease
2019 (COVID-19) contains high titers of neutralizing antibodies, which has potential effects …

BACKGROUND A novel coronavirus has caused an international outbreak. Currently, there
are no specific therapeutic agents for coronavirus infections. Convalescent plasma (CP) …

Objectives: Current evidence favors plasma to be effective against coronavirus disease
2019 (COVID-19) in critically ill patients in the early stages of infection. We investigated the …